Senseonics Holdings, Inc.
Senseonics Holdings, Inc. develops and commercializes the Eversense continuous glucose monitoring system for people with diabetes. The company is based in the United States and sells implantable CGM sensors, transmitters, and related components through healthcare and distribution channels in the U.S. and Europe.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEversense glucose monitoring systems that measure glucose continuously for diabetes management.
Disposable sensor components and other recurring consumables used with the system.
External transmitter devices and related hardware used to read and transmit glucose data.
Training, patient support, and commercialization-related services tied to adoption and retention.
Customers
Senseonics sells primarily to commercial partners, distributors, and healthcare channels that then place Eversense with patients and healthcare providers. End users are diabetes patients and their care teams, with recurring demand driven by sensor replacement and ongoing system use. The company also relies on healthcare professionals and payor coverage decisions because those influence adoption and repeat usage.
Partners that buy Eversense products for resale and commercialization support.
End users of the CGM system who drive recurring sensor consumption and retention.
Clinics and prescribers that recommend, implant, and monitor the system.
Insurers and coverage decision-makers that determine patient access and adoption.
Strategy
Senseonics’ strategy centers on expanding adoption of Eversense, improving patient access, and strengthening commercialization control over its product. The company also focuses on payer coverage, patient retention, and product development such as Eversense 365 in the United States, because recurring sensor use and long-term adoption are central to the model.
Recurring sensor demand depends on keeping patients on the platform.
Reimbursement decisions materially affect device uptake and persistence.
Product improvements are needed to compete with larger CGM rivals.
Owning more of the sales and distribution process can improve execution.
Geography
Q1/2026Senseonics operates in the United States and in markets outside the United States, with revenue disclosed across those two primary regions. The company’s commercial footprint is tied to diabetes device adoption, reimbursement, and regulatory access in each market, which makes geography important to both distribution and market penetration. Its European business has also involved local commercial and tender arrangements, while U.S. commercialization has been central to the Eversense franchise.
Share of the revenue the company reports by geography.
Risks
Senseonics faces concentration risk because a large share of revenue has historically depended on a small number of commercialization partners, especially Ascensia. It also competes in a fast-moving CGM market against larger device makers, while reimbursement, regulatory approvals, manufacturing execution, and patient retention all directly affect demand and recurring sensor sales.
- Dependence on Ascensia commercializationImpact: HighLikelihood: High
A substantial portion of historical revenue came from one commercial partner.
Exposure - Competitive pressure in CGMImpact: HighLikelihood: High
Dexcom, Abbott, and Medtronic have larger scale and broad market presence.
Exposure - Reimbursement and coverage riskImpact: HighLikelihood: Medium
Patient uptake depends heavily on insurance coverage and payor policy.
Exposure: U.S. and international patient access
- Manufacturing and distribution executionImpact: MediumLikelihood: Medium
The product requires reliable sterilization, inventory handling, and delivery.
Exposure: Sensor availability and product quality
- Regulatory and product acceptance riskImpact: MediumLikelihood: Medium
CGM adoption depends on approvals, certifications, and clinician confidence.
Exposure: Launch timing and market expansion
Accounting
Judgemental itemsSales through distributors and consignment channels are recognized at different points.
Impact: Can shift revenue between periods
Prompt-pay discounts, tier pricing, and revenue share require estimates.
Impact: Affects net revenue and contract assets
Commercialization agreements create timing differences in billing and performance.
Impact: Can materially affect balance sheet presentation
Device products require reserves for excess inventory and product issues.
Impact: Affects cost of sales and operating expenses
Equity awards are a recurring non-cash expense for a development-stage medtech company.
Impact: Affects operating loss and diluted share metrics
Similar listed companies
Publicly listed companies with a comparable business focus.
DexCom, Inc
DXCM · Surgical & Medical Instruments & Apparatus
DexCom is a U.S.
Glucotrack, Inc.
GCTK · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care, Inc
TNDM · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy.
Insulet Corporation
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
Profusa, Inc.
NVACW · Surgical & Medical Instruments & Apparatus
Medtronic plc
MDT · Electromedical & Electrotherapeutic Apparatus
Medtronic plc designs, manufactures, and sells medical technologies used to diagnose, treat, and manage chronic and acute conditions across the body.
Last updated: 24/09/2026